deborah lebman - Search Results

Year	Number of Results
2002	1
2003	1
2005	1
2008	2
2009	1
2010	2
2011	1
2012	1
2023	1

1

Cross-talk at the crossroads of sphingosine-1-phosphate, growth factors, and cytokine signaling.

Lebman DA, Spiegel S. Lebman DA, et al. J Lipid Res. 2008 Jul;49(7):1388-94. doi: 10.1194/jlr.R800008-JLR200. Epub 2008 Apr 2. J Lipid Res. 2008. PMID: 18387885 Free PMC article. Review.

2

Mechanism of resistance to phagocytosis and pulmonary persistence in mucoid Pseudomonas aeruginosa.

Rowe WJ 3rd, Lebman DA, Ohman DE. Rowe WJ 3rd, et al. Among authors: lebman da. Front Cell Infect Microbiol. 2023 Mar 15;13:1125901. doi: 10.3389/fcimb.2023.1125901. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37009499 Free PMC article.

3

Photocaged permeability: a new strategy for controlled drug release.

Dcona MM, Mitra D, Goehe RW, Gewirtz DA, Lebman DA, Hartman MC. Dcona MM, et al. Among authors: lebman da. Chem Commun (Camb). 2012 May 16;48(39):4755-7. doi: 10.1039/c2cc30819c. Epub 2012 Apr 4. Chem Commun (Camb). 2012. PMID: 22473358 Free PMC article.

4

Lysophosphatidic acid-induced p21Waf1 expression mediates the cytostatic response of breast and ovarian cancer cells to TGFβ.

Wu J, Mukherjee A, Lebman DA, Fang X. Wu J, et al. Among authors: lebman da. Mol Cancer Res. 2011 Nov;9(11):1562-70. doi: 10.1158/1541-7786.MCR-11-0340. Epub 2011 Sep 2. Mol Cancer Res. 2011. PMID: 21890597 Free PMC article.

5

Preservation of splenic immunocompetence after splenic artery angioembolization for blunt splenic injury.

Malhotra AK, Carter RF, Lebman DA, Carter DS, Riaz OJ, Aboutanos MB, Duane TM, Ivatury RR. Malhotra AK, et al. Among authors: lebman da. J Trauma. 2010 Nov;69(5):1126-30; discussion 1130-1. doi: 10.1097/TA.0b013e3181f9fa1e. J Trauma. 2010. PMID: 21068617

6

Surface engineering of macrophages with nanoparticles to generate a cell-nanoparticle hybrid vehicle for hypoxia-targeted drug delivery.

Holden CA, Yuan Q, Yeudall WA, Lebman DA, Yang H. Holden CA, et al. Among authors: lebman da. Int J Nanomedicine. 2010 Feb 2;5:25-36. Int J Nanomedicine. 2010. PMID: 20161985 Free PMC article.

7

Heterogeneity in the transforming growth factor beta response of esophageal cancer cells.

Lebman DA, Edmiston JS, Chung TD, Snyder SR. Lebman DA, et al. Int J Oncol. 2002 Jun;20(6):1241-6. Int J Oncol. 2002. PMID: 12012005

8

Transforming growth factor beta specifically enhances IgA production by lipopolysaccharide-stimulated murine B lymphocytes. J. Exp. Med. 1989. 170: 1039-1044.

Coffman RL, Lebman DA, Shrader B. Coffman RL, et al. Among authors: lebman da. J Immunol. 2009 Jan 1;182(1):8-13. J Immunol. 2009. PMID: 19109127 No abstract available.

9

Transforming growth factor-beta is an endogenous radioresistance factor in the esophageal adenocarcinoma cell line OE-33.

Kim AH, Lebman DA, Dietz CM, Snyder SR, Eley KW, Chung TD. Kim AH, et al. Among authors: lebman da. Int J Oncol. 2003 Dec;23(6):1593-9. Int J Oncol. 2003. PMID: 14612931

10

Sphingosine kinases and sphingosine-1-phosphate are critical for transforming growth factor beta-induced extracellular signal-regulated kinase 1 and 2 activation and promotion of migration and invasion of esophageal cancer cells.

Miller AV, Alvarez SE, Spiegel S, Lebman DA. Miller AV, et al. Among authors: lebman da. Mol Cell Biol. 2008 Jun;28(12):4142-51. doi: 10.1128/MCB.01465-07. Epub 2008 Apr 21. Mol Cell Biol. 2008. PMID: 18426913 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

11 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year